Compare Incyte Corporation (INCY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Incyte Corporation trades at $113.22 (market cap $22.85B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.34 (market cap $141.25M). The key difference: Incyte Corporation is far larger — about 161.8× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| INCY | KOLD | |
|---|---|---|
Market Cap | $22.85B | $141.25M |
Volume | 1,927,029 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $49.39 |
52-Week Low | $83.80 | $13.58 |
Typical Hold Time | 33 Days | 10 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
KOLD is trading at $24.52, down 1.29% over the past day, with a bearish technical signal driven by moving averages. The stock lacks key financial ratio data, and recent news highlights volatility in natural gas markets, with record-high U.S. production and geopolitical tensions influencing sentiment.
The outlook for KOLD is clouded by weak technicals and fundamental data gaps. Investment opportunities are limited without clear earnings or valuation metrics, while risks include energy market volatility and competitive pressures from high natural gas supply.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
